NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Additional thoughts on this phase 1b neoantigen trial, the results of which may be implications for DCVac.

Patients who did not receive dexamethasone—a highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in patients with glioblastoma—generated circulating polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumour-infiltrating T cells

The opposite was true also — patients who had dexamethazone has decreased T-cell responses. Thus DEX might possibly interfere with DCVax effectiveness.

Has this been accounted for in the phase 3 trial, since DEX is fairly common for glioblastoma patients?